Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05204537
Other study ID # 3822
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2020
Est. completion date March 30, 2022

Study information

Verified date May 2023
Source University of Milano Bicocca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Thoracic complications directly or indirectly consequence of Coronavirus Disease 2019 (COVID-19) (including either pathologies strictly related to the infection, or iatrogenic effects of therapeutic attempts to treat it) have been described during the pandemic. Many of the above conditions often require a surgical approach but, based on published data reporting high early postoperative morbidity and mortality, many experts initially advised against any referral to surgery in COVID-19 patients. Therefore, the issue is if salvage surgical approach should be always excluded or could be considered when it represents the only remaining effective option. In the absence of solid data and recommendations, this is a demanding challenge for thoracic surgeons. The investigators have coordinated a multicenter study to collect the experience of several worldwide high-volume thoracic surgery departments. Their objective is to investigate efficacy and safety of surgery in COVID-19 patients who developed thoracic complications that required operative management.


Description:

The year of 2019 has been characterized by the rise of a new respiratory infection named "severe acute respiratory syndrome coronavirus 2" (Sars-CoV-2). It has rapidly diffused over the world. By November 2021, there were more than 252.000.000 confirmed cases and more than 5.000.000 death worldwide. A significant amount of effort has been exerted to better understand its optimal management. Mild COVID-19 disease condition can cause symptoms such as fever, cough and shortness of breath as well as tiredness, muscle aches. Yet severe and critical disease state are characterized by dramatic and life-threatening symptoms. Among those, the most common is pneumonia which quickly progress to Acute respiratory distress syndrome (ARDS). Pneumatoceles, parenchymal air-filled cysts, seem to occur more likely in COVID-19 patients as well. The second critical point is blood hypercoagulability, probably due to vascular endothelial cell injury, which is manifested by a higher incidence of venous and arterial thrombosis and pulmonary embolism requiring prolonged anticoagulant prophylactic treatment; these conditions can conspire to unexpected intrapleural bleeding. Moreover, these patients often develop co-infections which lead to further complications such as empyema and septic shock. The above conditions often require a surgical approach but, based on published data reporting high early postoperative morbidity and mortality, many experts initially advised against any referral to surgery in COVID-19 patients. Therefore, the issue is if salvage surgical approach should be always excluded or could be considered when it represents the only remaining effective option. In the absence of solid data and recommendations, this is a demanding challenge for thoracic surgeons. Investigators have coordinated a multicenter study to collect the experience of several worldwide high-volume thoracic surgery departments. Their objective is to investigate efficacy and safety of surgery in COVID-19 patients who developed thoracic complications that required operative management. Their first aim is to estimate postoperative survival at 30 days, other endpoints are: postoperative complications incidence and prognostic factors for 30 days mortality and morbidity. The investigators have designed an observational retrospective multicenter international study, involving nine experienced thoracic surgery departments, in five different countries. This study has been approved by the research ethics committee at the lead centre and has been conducted in accordance with the Declaration of Helsinki. At the other centers, local principal investigators have been asked with getting approvals. The study population consists of patients who developed in-hospital COVID-19 thoracic complications, surgically managed from March 2020 to May 2021. Thoracic complication are defined as any condition involving the thorax, directly or indirectly consequence of COVID-19, including either pathologies strictly related to the infection, or iatrogenic effects of therapeutic attempts to treat it. A wide variety of surgical procedures have been included. Patients undergone chest tube placement alone are not included in the study. Data are retrospectively collected and entered into a dedicated password-protected database. Demographic, anamnestic, clinical, surgical and outcome-related variables are derived from medical and nursing records, laboratory reports, radiological findings. Patients will be followed up to discharge or to 30 days after surgery if discharge occurred before. Follow up consists of an outpatient clinic visit, including physical examination and chest X-Ray; patients discharged with long-COVID, who are under quarantine at home, according to the regulations in force, are tele medically evaluated. Primary end-point is postoperative survival at 30 days from surgery. Secondary end-points are postoperative complications. Postoperative complications are graded according to the Thoracic Morbidity and Mortality Classification System from grade I (no need for treatment or intervention) to grade V (leading to death). The target sample size of about 80 subjects has been derived in order to estimate survival at 30 days post-surgery with a precision of 0.194 (total width of the 95% confidence interval) assuming a survival of 0.77. Baseline characteristics of patients will be described as median (I and III quartiles) and frequencies (percentage). Cumulative incidence of in-hospital mortality and discharge will be estimated by the Aalen-Johansen estimator. Overall mortality at 30 days are obtained by Kaplan-Meier and compared among groups by the log-rank test. In order to account for time to death a multivariable Cox regression model has been applied to identify the variables associated with mortality 30 days after surgery. A multivariable logistic model will be applied to identify variables associated with post-operative complications. The variables included in the models are clinical parameters (age, sex, maximum ventilator support) with the addition of the variables associated with outcomes in the unadjusted analyses (renal insufficiency, pulmonary hypertension, complications surgically treated classified as infective affection (eg. empyema/pneumatoceles) compared to others (eg. pneumothorax, hemothorax, etc.) and type of surgery). Results are presented by hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CI). Data will be analyzed using R software (version 4.0.3).


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date March 30, 2022
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years old; - molecular diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection through nose-pharyngeal swab or bronchoalveolar lavage via real-time polymerase chain reaction (PCR) analysis; - hospital admission because of clinical/radiological diagnosis of pneumonia; - onset of thoracic complications during hospitalization or prolonged hospitalization requiring thoracic surgical procedures; - hospital admission from 01/03/2020 to 31/05/2021. Exclusion Criteria: -

Study Design


Intervention

Procedure:
Lung parenchyma resection
Lung parenchyma removal
Empyemectomy
Intrapleural cavity effusion removal, parietal pleura removal.

Locations

Country Name City State
Brazil Thoracic Surgery, Hospital Federal do Andaraí Rio de Janeiro
India Sunrise hospital. Kochi
India Thoracic Surgery, Sir Ganga Ram Hospital New Delhi
Italy Thoracic Surgery, ASST Spedali Civili Brescia
Italy San Gerardo Hospital Monza
Italy Thoracic Surgery, San Camillo Forlanini Hospital. Roma
Italy Thoracic Surgery, San Giovanni Battista Molinette Hospital Turin
United Kingdom Thoracic Surgery, University College London Hospitals London
United States Thoracic Surgery, NYU Langone Health New York New York

Sponsors (2)

Lead Sponsor Collaborator
University of Milano Bicocca Azienda Ospedaliera San Gerardo di Monza

Countries where clinical trial is conducted

United States,  Brazil,  India,  Italy,  United Kingdom, 

References & Publications (6)

Chang SH, Chen D, Paone D, Geraci TC, Scheinerman J, Bizekis C, Zervos M, Cerfolio RJ. Thoracic surgery outcomes for patients with Coronavirus Disease 2019. J Thorac Cardiovasc Surg. 2021 Dec;162(6):1654-1664. doi: 10.1016/j.jtcvs.2021.01.069. Epub 2021 J — View Citation

COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38. doi: 10.1016/S0140-6736(20)31182-X. Epub 2020 May 29. Erratum In: Lancet. 2020 Jun 9;: — View Citation

Hamad AM, El-Saka HA. Post COVID-19 large pneumatocele: clinical and pathological perspectives. Interact Cardiovasc Thorac Surg. 2021 Jul 26;33(2):322-324. doi: 10.1093/icvts/ivab072. — View Citation

Knisely A, Zhou ZN, Wu J, Huang Y, Holcomb K, Melamed A, Advincula AP, Lalwani A, Khoury-Collado F, Tergas AI, St Clair CM, Hou JY, Hershman DL, D'Alton ME, Huang YY, Wright JD. Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical Procedures. Ann Surg. 2021 Jan 1;273(1):34-40. doi: 10.1097/SLA.0000000000004420. — View Citation

McGuinness G, Zhan C, Rosenberg N, Azour L, Wickstrom M, Mason DM, Thomas KM, Moore WH. Increased Incidence of Barotrauma in Patients with COVID-19 on Invasive Mechanical Ventilation. Radiology. 2020 Nov;297(2):E252-E262. doi: 10.1148/radiol.2020202352. Epub 2020 Jul 2. — View Citation

Scarci M, Raveglia F, Bortolotti L, Benvenuti M, Merlo L, Petrella L, Cardillo G, Rocco G. COVID-19 After Lung Resection in Northern Italy. Semin Thorac Cardiovasc Surg. 2022 Summer;34(2):726-732. doi: 10.1053/j.semtcvs.2021.03.038. Epub 2021 May 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative survival Overall survival at 30 days from surgery day 30
Secondary Postoperative complications Postoperative complications were graded according to the Thoracic Morbidity and Mortality Classification System from grade I (no need for treatment or intervention) to grade V (leading to death) 30 days from surgery
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure